Bayerische Motoren Werke ADR (BMWYY)

For a variety of reasons, hospitals can disagree with Medicare Advantage insurance providers and they part ways. When a hospital cancels or fails to renew its contract with a health insurer, the patients who had coverage with that insurer often have to choose between staying with that insurer and getting care from the shrinking network of providers or ditch the MA plan. Reports indicate that thousands of patients ditch MA plans once the health insurer and hospital fail to continue their relationship.

Libertyville, IL () May 1, 2025 -- BMW owners gain expert local support as Auto Lab Libertyville delivers certified maintenance and repair solutions with 30 years of trusted service.

Wheel Paints’ advanced alloy wheel paints provide greater convenience to refurbishers and alloy wheel manufacturers.

HealthLynked (OTCQB: HLYK) today announced a major enhancement to its appointment booking capabilities, further expanding patient access to care across its growing network of healthcare providers. “At HealthLynked, our mission is to connect patients with the best possible healthcare, faster and more efficiently,” said Dr. Michael Dent, CEO of HealthLynked. “These latest enhancements expand access to care — whether through in-network booking, concierge appointment requests, or specialty-based provider matching. Just as importantly, our new provider review system gives patients real feedback from other users, helping them make better, more confident decisions about their healthcare. Together, these improvements strengthen the patient experience and drive better health outcomes.”

TransCode Therapeutics (NASDAQ: RNAZ) reported continued progress in its Phase 1a trial of TTX-MC138, an RNA-based therapeutic targeting microRNA-10b in metastatic cancer. Thirteen patients have received at least one dose across four dosing levels, with no significant toxicities observed. Eight patients remain in the trial, with two showing stable disease after seven months. Early PK/PD data indicate target engagement and a dose-response relationship consistent with preclinical findings. The results support advancing the trial to Phase 1b for expanded safety and anti-tumor activity evaluation.

Scinai Immunotherapeutics (NASDAQ: SCNI) will host a webinar May 7 at 11:30 a.m. EST to discuss the treatment potential of Pincell’s novel monoclonal antibody, PC111, for rare skin conditions Pemphigus Vulgaris and SJS/TEN. The session will cover unmet medical needs, PC111’s mechanism targeting soluble Fas ligand, and development plans. The event follows Scinai’s March agreement to acquire Pincell and a related €12 million grant application under Poland’s FENG program. Panelists include executives from Scinai and Pincell, with a live Q&A segment.

A team of researchers based at the Amsterdam University Medical Center (UMC) have come up with a new test that can diagnose bacterial meningitis rapidly and with a high degree of accuracy. The test is conducted on cerebrospinal fluid and levels of a protein called CRP are measured. This same protein is also currently relied upon when diagnosing many other bacterial infections.

The development of treatments for rare diseases remains one of the most pressing challenges in modern medicine. Despite significant advancements in healthcare, many rare diseases still have no approved treatments, and patients often face grim prospects. The market for treatments in this space is substantial, as rare diseases collectively affect millions of people worldwide. Among those working tirelessly to fill these gaps is Soligenix (NASDAQ: SNGX), a biopharmaceutical company that is leading the way with innovative therapies for rare and difficult-to-treat diseases, particularly early-stage cutaneous T-cell lymphoma, a rare form of cancer that affects the skin.

Cancer remains one of the deadliest diseases worldwide. Globally, the World Health Organization reports that the number of deaths will surpass 9.7 million in 2024, with a projected 20 million new cancer cases diagnosed; WHO also noted that it anticipates the cancer burden increasing an estimated 77% by 2050 ( https://ibn.fm/VfZlY ). These numbers underscore the urgency of ongoing cancer research and the need for more effective cancer treatments.

A team of researchers has leveraged a technique called temporal learning to train an AI system to predict the likelihood of brain cancer recurring in kids diagnosed with gliomas. This AI model uses the magnetic resonance images periodically captured after the kids have received treatment for the gliomas.

Nutriband (NASDAQ: NTRB) has released a shareholder letter from CEO Gareth Sheridan outlining key achievements in 2024 and plans for 2025, centered on advancing its AVERSA abuse-deterrent transdermal technology. The company is transitioning from feasibility to commercial development of AVERSA Fentanyl in partnership with Kindeva Drug Delivery, targeting a pivotal Human Abuse Liability clinical trial and NDA filing. AVERSA Fentanyl and AVERSA Buprenorphine could reach peak annual sales of up to $200 million and $130 million respectively. Nutriband also expanded its global patent portfolio to 46 countries and raised $8.4 million in a non-brokered placement. The company expects continued revenue growth in 2025 from its Pocono Pharma subsidiary, driven by its partnership with KT Tape.

Nutriband (NASDAQ: NTRB) is earning widespread recognition for the board’s leadership, expertise and innovation across a variety of platforms. Sheridan has recently been acknowledged in several high-profile ways that affirm his growing influence as a respected professional in the healthcare and business sectors. From being named a finalist for the prestigious EY Entrepreneur of the Year Awards to providing key insights in a BBC News feature on Irish companies operating internationally and sharing their strategic vision in a wide-ranging interview, NTRB’s voice is increasingly shaping discussions around entrepreneurship, innovation and the future of healthcare.

April 30, 2025 -- A Legacy of Excellence

Cancer remains one of the most formidable health challenges worldwide, necessitating relentless research to uncover effective treatments. Continuous scientific inquiry has led to groundbreaking therapies, offering hope to millions. A recent development in this arena is Calidi Biotherapeutics’ (NYSE American: CLDI) announcement of promising preclinical results for its systemic RTNova platform, highlighting the critical role of research in combating cancer.

Calidi Biotherapeutics (NYSE American: CLDI) announced the selection of IL15 superagonist (IL15-IL15Ra) as the first therapeutic payload for its systemic antitumor virotherapy platform, RTNova. Preclinical data presented at the AACR Annual Meeting show that Calidi’s engineered vaccinia virus can deliver IL15 superagonist directly into the tumor microenvironment, significantly boosting immune response and tumor elimination while minimizing systemic toxicity. The RTNova platform aims to treat metastatic cancers by enabling systemic delivery of tumor-targeted virotherapies.

April 27, 2025 -- A Legacy of Excellence in European Car Care

April 27, 2025 -- Expert Mercedes & BMW Repair in West Palm Beach

Nutriband (NASDAQ: NTRB), a company focused on the development of a portfolio of transdermal pharmaceutical products, was featured in a recent article that discussed its innovative AVERSA(TM) abuse-deterrent technology and business model. “AVERSA technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, such as fentanyl, while making sure that these drugs remain accessible to patients who need them. The technology is covered by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, Canada, Mexico, Australia, and China, with recent extensions into Macao,” the article reads.

A new study focusing on twins has found that individuals with a larger presence of certain bacteria types could have a higher likelihood of developing multiple sclerosis . These findings could offer new ways to halt the disease’s progression or prevent it altogether.

Las Vegas, Nevada - April 24, 2025 - Mods4cars is now launching its retrofit SmartTOP convertible top control system for the 7th Gen Ford Mustang convertible. “We are delighted that we can now also offer a smart convertible top solution for the 7th Gen Ford Mustang Convertible,” says PR spokesman Sven Tornow. The SmartTOP modules are retrofitted to the vehicle to make the convertible top more convenient to operate.

Stem cells are the “master cells” within the body because they can grow into any needed type of specialized cell in one’s body. As cancer treatment advances, these cells are proving to be a lifesaver for many people diagnosed with blood cancers like leukemia, myeloma and lymphoma.

Limo SF VIP (888-888-0195) announces an expanded VIP transportation service available in the San Francisco Bay Area, offering exclusive experiences suited to high-end weddings, special events, luxury city tours, wine tours, and airport transfers.

UnitedHealth Group, the largest health insurance firm in the U.S., has reduced its revenue forecast for 2025 after its customers on Medicare Advantage made use of their policies a lot more than the company had anticipated. The first quarter of the year registered a lower financial performance than the company had expected.

Nutriband (NASDAQ: NTRB) continues to solidify its leadership in the development of abuse-deterrent transdermal pharmaceuticals. In February, the company received a trademark registration from the U.S. Patent and Trademark Office (“USPTO”) for “Nutriband(TM),” covering pharmaceutical and product R&D. This comes in addition to a newly granted patent in Macao for its proprietary AVERSA(TM) transdermal system, bringing the total number of countries granting protection to 46.

Despite the passage of time since the pandemic, COVID-19 continues to pose a significant global health threat. Recent data from the World Health Organization (“WHO”) indicates that during the 28-day period from Jan. 6 to Feb. 2, 2025, more than 147,000 new COVID-19 cases were reported globally, representing a 16% decrease compared to the previous period ( https://ibn.fm/viChU ). However, during the same timeframe, approximately 4,500 new deaths were reported, marking a 28% increase. This underscores the persistent danger of the virus and the urgent need for effective protective measures and treatments.